Status:
ENROLLING_BY_INVITATION
Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Heart Failure Management
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Atherosclerotic Cardiovascular Disease
Heart Failure
Eligibility:
All Genders
18+ years
Brief Summary
This is a survey-based study conducted among cardiologists and nephrologists treating people with Atherosclerotic Cardiovascular Disease (ASCVD), Heart Failure (HF) and Chronic Kidney Disease (CKD). S...
Eligibility Criteria
Inclusion
- Informed consent obtained before any study related activities (study-related activities are any procedure related to recording of data according to the protocol).
- Male or female, age above 18 years at the time of signing informed consent.
- Is a nephrologist or cardiologist. Cardiologists may be a mix of Interventional Cardiology, Heart Failure (HF) Specialist, General Cardiology, Preventative Cardiology, Cardiac Electrophysiology, Cardio-Oncology or Echocardiography (India only).
- Has been in specialty practice greater than or equal to 3 years.
- If cardiologist, sees at least 15 people with Atherosclerotic Cardiovascular Disease (ASCVD) with or without Chronic Kidney Disease (CKD) per month.
- If nephrologist, sees at least 20 people with ASCVD and CKD per month.
Exclusion
- Previous participation in this study. Participation is defined as having given informed consent in this study.
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- If nephrologist, is only using dialysis to treat people with ASCVD and CKD.
- Does not meet inclusion criteria requirements.
Key Trial Info
Start Date :
September 18 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 31 2025
Estimated Enrollment :
608 Patients enrolled
Trial Details
Trial ID
NCT07160829
Start Date
September 18 2025
End Date
October 31 2025
Last Update
September 30 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Sydney, Australia, 2060
2
Novo Nordisk Investigational Site
Bangalore, Karnataka, India
3
Novo Nordisk Investigational Site
Seoul, South Korea
4
Novo Nordisk Investigational Site
Bangkok, Thailand